184 related articles for article (PubMed ID: 34789015)
1. Concomitant genetic alterations are associated with plasma D-dimer level in patients with non-small-cell lung cancer.
Chang F; Zhang H; Chen C; Ke Z; Zhao M; Fan X; Zhang Y
Future Oncol; 2022 Feb; 18(6):679-690. PubMed ID: 34789015
[TBL] [Abstract][Full Text] [Related]
2. The role of plasma D-dimer levels for predicting lymph node and mediastinal lymph node involvement in non-small cell lung cancer.
Gao XL; Wang SS; Cao DB; Liu W
Clin Respir J; 2018 Jun; 12(6):2151-2156. PubMed ID: 29498801
[TBL] [Abstract][Full Text] [Related]
3. Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution.
Li D; Ding L; Ran W; Huang Y; Li G; Wang C; Xiao Y; Wang X; Lin D; Xing X
Thorac Cancer; 2020 Sep; 11(9):2580-2589. PubMed ID: 32729257
[TBL] [Abstract][Full Text] [Related]
4. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
Aggarwal C; Thompson JC; Black TA; Katz SI; Fan R; Yee SS; Chien AL; Evans TL; Bauml JM; Alley EW; Ciunci CA; Berman AT; Cohen RB; Lieberman DB; Majmundar KS; Savitch SL; Morrissette JJD; Hwang WT; Elenitoba-Johnson KSJ; Langer CJ; Carpenter EL
JAMA Oncol; 2019 Feb; 5(2):173-180. PubMed ID: 30325992
[TBL] [Abstract][Full Text] [Related]
5. A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Zaborowska-Szmit M; Kowalski DM; Piórek A; Krzakowski M; Szmit S
Pharmacol Rep; 2016 Dec; 68(6):1140-1148. PubMed ID: 27588390
[TBL] [Abstract][Full Text] [Related]
6. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive value of plasma D-dimer in advanced non-small cell lung cancer patients undergoing first-line chemotherapy.
Ge LP; Li J; Bao QL; Chen P; Jiang Q; Zhu LR
Clin Transl Oncol; 2015 Jan; 17(1):57-64. PubMed ID: 24997087
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of preoperative plasma D-dimer level in patients with surgically resected clinical stage I non-small cell lung cancer: a retrospective cohort study.
Kaseda K; Asakura K; Kazama A; Ozawa Y
J Cardiothorac Surg; 2017 Nov; 12(1):102. PubMed ID: 29183325
[TBL] [Abstract][Full Text] [Related]
9. Plasma D-Dimer Level Correlates with Age, Metastasis, Recurrence, Tumor-Node-Metastasis Classification (TNM), and Treatment of Non-Small-Cell Lung Cancer (NSCLC) Patients.
Guo J; Gao Y; Gong Z; Dong P; Mao Y; Li F; Rong J; Zhang J; Zhou Y; Feng H; Guo H; Gu L; An M; Wen K; Zhang J
Biomed Res Int; 2021; 2021():9623571. PubMed ID: 34712737
[TBL] [Abstract][Full Text] [Related]
10. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of plasma D-dimer levels in lung carcinoma.
Komurcuoglu B; Ulusoy S; Gayaf M; Guler A; Ozden E
Tumori; 2011; 97(6):743-8. PubMed ID: 22322841
[TBL] [Abstract][Full Text] [Related]
12. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
14. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
[TBL] [Abstract][Full Text] [Related]
16. Preoperative plasma D-dimer levels predict survival in patients with operable non-small cell lung cancer independently of venous thromboembolism.
Zhang PP; Sun JW; Wang XY; Liu XM; Li K
Eur J Surg Oncol; 2013 Sep; 39(9):951-6. PubMed ID: 23810331
[TBL] [Abstract][Full Text] [Related]
17. Value of fibrinogen and D-dimer in predicting recurrence and metastasis after radical surgery for non-small cell lung cancer.
Jiang HG; Li J; Shi SB; Chen P; Ge LP; Jiang Q; Tang XP
Med Oncol; 2014 Jul; 31(7):22. PubMed ID: 24861920
[TBL] [Abstract][Full Text] [Related]
18. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive value of plasma D-dimer levels in patients with small-cell lung cancer.
Zhang C; Jia Y; Jia Y; Zhang X; Li K
Int J Clin Oncol; 2018 Dec; 23(6):1070-1075. PubMed ID: 30168089
[TBL] [Abstract][Full Text] [Related]
20. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
